Compound ID | 374
AC98-6446
Class: Glycopeptide
| Spectrum of activity: | Gram-negative |
| Details of activity: | Activity against MRSA |
| Institute where first reported: | Wyeth Pharma (Pfizer, USA) |
| Year first mentioned: | 2002 |
| Highest developmental phase: | Preclinical |
| Development status: | Inactive |
| Reason Dropped: | When Pfizer took over Wyeth, these were not continued. Need for IV MRSA agents was less acute at the time. - (LS) |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.